Ciclofilin制药公司的药品乙肝演示抗纤维化活动

StephenW

Ciclofilin Pharmaceuticals' HBV Drug Demonstrates Anti-Fibrotic Activity

June 24, 2015 08:00 ET | Source: Ciclofilin Pharmaceuticals Inc.

SAN DIEGO, June 24, 2015 (GLOBE NEWSWIRE) -- Ciclofilin Pharmaceuticals Inc. ("Ciclofilin" or the "Company"), a hepatitis B virus ("HBV") drug developer, announced today its lead antiviral drug demonstrated anti-fibrotic activity in a liver fibrosis animal model.

Ciclofilin's lead candidate drug, CPI-431-32, is a proprietary cyclophilin antagonist that potently inhibits HBV. CPI-431-32 acts primarily by inhibiting HBV's ability to hijack and utilize the host cell protein, cyclophilin, to propagate infection. In vitro experiments conducted in collaboration with Dr. Philippe Gallay of the Scripps Research Institute in San Diego and with partial support of the National Research Council (NRC) of Canada have demonstrated that CPI-431-32 targets multiple stages of the HBV life cycle, including viral entry into cells, replication, HBsAg production, and generation of cccDNA.

Fibrosis is a serious consequence of chronic HBV infection and contributes significantly to the development of cirrhosis and liver cancer.  Despite the reduction in viral load seen with current nucleos(t)ide drug treatments, patients still remain at a high risk for the development of liver cancer.  

The Company's fibrosis study was conducted by Stelic Institute Inc. (Tokyo, Japan). In the model, liver damage and resulting fibrosis was induced by streptozotocin and a high fat diet.  CPI-431-32 was administered to mice for 21 days via oral gavage. Fibrosis was assessed histologically. After 3 weeks treatment, fibrosis was reduced by approximately 55% compared to the control group (p<0.01). Importantly, in addition to demonstrating anti-fibrosis efficacy, the drug was safe and well-tolerated.

"We are very encouraged with these results from the mouse model, as the data indicate our drug has an additional mode of action beyond its established antiviral activity," commented Dr. Robert Foster, the Company's CEO. "Indeed, the new finding with CPI-431-32 highlights the drug's potential to alleviate liver disease better than existing hepatitis B drugs.  In addition, we believe that many currently proposed antiviral strategies searching for a HBV cure cannot offer an added direct anti-fibrotic benefit similar to that seen with CPI-431-32. While HBV elimination is the most important strategy for treating chronic hepatitis B, the ultimate goal is to restore normal liver function and eliminate the risk of cirrhosis and liver cancer."

About Ciclofilin:

Ciclofilin is a life sciences company based in San Diego, California, with R&D facilities in Edmonton, Canada. The company's lead drug, CPI-431-32, is uniquely designed to specifically target the host and not the virus. By targeting the host, CPI-431-32 interferes with the necessary cellular components that allow HBV to persist in the liver and cause disease. CPI-431-32 blocks HBV at multiple stages of the viral life cycle, including virus entry and replication, and also stimulates the immune system to attack the virus. CPI-431-32 may also reduce liver disease through additional mechanisms independent of the antiviral activities (liver inflammation and fibrosis, liver cirrhosis, and hepatocellular carcinoma).
- See more at: http://globenewswire.com/news-re ... thash.lMqFq0XW.dpuf
                             

StephenW

Ciclofilin制药公司的药品乙肝演示抗纤维化活动
  2 0 1 23
打印
2015年6月24日08:00 ET |来源：Ciclofilin制药公司

圣迭戈，2015年6月24日（GLOBE NEWSWIRE） - Ciclofilin制药公司（“Ciclofilin”或“公司”），乙型肝炎病毒（“乙肝”）的药物开发商，今日宣布其领先抗病毒药物表现出抗纤维化活性在肝纤维化动物模型。

Ciclofilin的领先候选药物，CPI-431-32，是一个专有的亲环素拮抗剂，有效抑制乙肝病毒。 CPI-431-32通过抑制乙肝病毒的劫持并利用宿主细胞蛋白，亲环，传播感染的能力，主要作用。在合作与斯克里普斯研究所圣地亚哥菲利普博士Gallay和进行体外实验，加拿大国家研究委员会（NRC）的部分支持表明，CPI-431-32针对乙肝病毒的生命周期中的多个阶段，包括病毒进入细胞，复制，乙肝表面抗原生产和产生的cccDNA的。

肝纤维化是慢性HBV感染的严重后果，显著为肝硬化和肝癌的发展作出贡献。尽管在病毒载量的减少看出与目前核苷（酸）的ide药物治疗，患者仍维持在一个较高的风险为肝癌的发展。

该公司的纤维化研究由Stelic研究所公司（日本东京）进行。在模型中，肝损伤和所得纤维化诱导菌素和高脂肪的饮食。 CPI-431-32施用到老鼠通过口服强饲法21天。纤维化组织学评估。治疗3周后，相比于对照组（p <0.01），纤维化减少了约55％。重要的是，除了显示出抗纤维化功效，药物是安全且耐受性良好。

“我们非常鼓舞，这些结果从小鼠模型，因为数据表明我们的药物有超出其既定抗病毒活性作用的附加模式，”博士评论说罗伯特·福斯特，该公司的首席执行官。 “事实上，新的发现与CPI-431-32突出了药物的潜力，缓解肝脏疾病比现有乙肝药物更好。此外，我们认为，目前的许多建议抗病毒策略寻找一种治疗乙肝不能提供一个直接添加抗类似于看到的CPI-431-32纤维化好处。尽管HBV消除是用于治疗慢性乙型肝炎的最重要策略，最终目的是恢复正常肝功能和消除肝硬化和肝癌的风险。“

关于Ciclofilin：

Ciclofilin是一家生命科学公司总部设在加利福尼亚州圣迭戈，研发设施在加拿大埃德蒙顿。公司的主导药物，CPI-431-32，设计独特，专门针对主机，而不是病毒。通过靶向宿主，CPI-431-32干扰了必要的细胞成分，使乙肝坚持在肝脏和引起疾病。 CPI-431-32块乙肝在病毒生命周期的多个阶段，包括病毒进入和复制，并且也刺激免疫系统攻击病毒。 CPI-431-32也可以通过独立的抗病毒活性（肝脏炎症和纤维化，肝硬化和肝细胞癌）的附加机制减少肝脏疾病。
- 在查看更多： http://globenewswire.com/news-re ... thash.lMqFq0XW.dpuf

yelanglms

CPI-431-32是新的药物吗？

StephenW

yelanglms 发表于 2015-6-25 09:24
CPI-431-32是新的药物吗？

只是临床前研究.

fs2002

期待成功面世

682256

CPI43132是抗纤维化的药物，不是抗病毒药。文中提到纤维化是肝硬化和肝癌的高危险因素。文中也提到治疗乙肝的根本还是抑制病毒，尽最大可能降低病毒载量。